These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31547288)

  • 1. Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.
    Yang H; Juang SY; Liao KF; Chen YH
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31547288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Sci Rep; 2015 Nov; 5():17150. PubMed ID: 26612282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study.
    Chen YR; Yang Y; Wang SC; Chiu PF; Chou WY; Lin CY; Chang JM; Chen TW; Ferng SH; Lin CL
    Nephrol Dial Transplant; 2013 Mar; 28(3):671-82. PubMed ID: 23223224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
    Wu PC; Wu CJ; Lin CJ; Pan CF; Chen CY; Huang TM; Wu CH; Lin SL; Chen YM; Chen L; Wu VC; ;
    Clin Pharmacol Ther; 2015 Oct; 98(4):442-9. PubMed ID: 26082272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease.
    Pan SY; Chiang WC; Chen PM; Liu HH; Chou YH; Lai TS; Lai CF; Chiu YL; Lin WY; Chen YM; Chu TS; Lin SL
    Sci Rep; 2017 Mar; 7():44013. PubMed ID: 28272424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
    Chen PM; Lai TS; Chen PY; Lai CF; Wu V; Chiang WC; Chen YM; Wu KD; Tsai TJ
    J Formos Med Assoc; 2014 Apr; 113(4):219-26. PubMed ID: 24512756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Nephrol Dial Transplant; 2015 Sep; 30(9):1518-25. PubMed ID: 25829323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
    de Morales AM; Goicoechea M; Verde E; Carbayo J; Barbieri D; Delgado A; Verdalles U; de Jose AP; Luño J
    J Nephrol; 2019 Aug; 32(4):581-587. PubMed ID: 30949987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive Impairment in Non-Dialysis-Dependent CKD and the Transition to Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Harhay MN; Xie D; Zhang X; Hsu CY; Vittinghoff E; Go AS; Sozio SM; Blumenthal J; Seliger S; Chen J; Deo R; Dobre M; Akkina S; Reese PP; Lash JP; Yaffe K; Kurella Tamura M;
    Am J Kidney Dis; 2018 Oct; 72(4):499-508. PubMed ID: 29728316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
    Chang TI; Zheng Y; Montez-Rath ME; Winkelmayer WC
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1401-1412. PubMed ID: 27354656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease.
    Takagi T; Kondo T; Omae K; Iizuka J; Kobayashi H; Yoshida K; Hashimoto Y; Tanabe K
    Int Urol Nephrol; 2016 Sep; 48(9):1421-7. PubMed ID: 27193433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD.
    Kurella Tamura M; Desai M; Kapphahn KI; Thomas IC; Asch SM; Chertow GM
    J Am Soc Nephrol; 2018 Aug; 29(8):2169-2177. PubMed ID: 29789430
    [No Abstract]   [Full Text] [Related]  

  • 17. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
    Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective associations between environmental heavy metal exposure and renal outcomes in adults with chronic kidney disease.
    Tsai CC; Wu CL; Kor CT; Lian IB; Chang CH; Chang TH; Chang CC; Chiu PF
    Nephrology (Carlton); 2018 Sep; 23(9):830-836. PubMed ID: 28632927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receipt of Nephrology Care and Clinical Outcomes Among Veterans With Advanced CKD.
    Fung E; Chang TI; Chertow GM; Thomas IC; Asch SM; Kurella Tamura M
    Am J Kidney Dis; 2017 Nov; 70(5):705-714. PubMed ID: 28811048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
    Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
    Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.